A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma.
During a Targeted Oncology Case-Based Roundtable event, Saad Zafar Usmani, MD, MBA, chief, Plasma Cell Disorders Program, director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discussed the case of a 51-year-old patients with newly-diagnosed multiple myeloma with 6 peers.
USMANI: How do you discuss the prognosis with your patients? We can use this patients case as an example.
MORAVINENI: From my perspective, you want to know which patient you are talking to, how educated they are, [and] how much they can understand. Are there any other family members with cancer? The psychosocial aspect of this, to me, is to think about how little or how [extensively] I should [go into detail] and how much the patient is interested to know about the prognosis. Some patients may not want to know at all at this point, but who is interested in talking about incurable cancer? Great benefit is out there, great therapies, expectation of several years of survival. All we need is confidence, literacy, and [adherence] that I will integrate and start from that point.
RUDOLPH: You know the prognosis clearly through cytogenetics. I dont know that staging carries too much weight in this day and age. As far as transplant eligibility, thats a tougher question. I think it really depends upon the transplanter. Everybody has different age criteria, so I leave it entirely in the hands of the transplanter. Ive had some that are aggressive, that want to offer transplant to a patient in their 80s, and then there are some thatll stop at patients in their mid-70s.
THOMAS: I agree with Dr Moravineni when he said some patients want to know and some dont want to know. So generally, when I first make a diagnosis, I dont go into prognosis too much unless they push me, and if they do, then I give them real-world perspective-type things. Ill say something like, When I first was in fellowship in the 90s, patients generally lived 2 to 3 years, and now weve come a long way with the treatments. Now an average patient may live 5 years, but I have many patients live over 10. It depends on the aggressiveness of your treatment, your overall health, that type thing. So thats usually how I approach it.
USMANI: I think those are very good points. One of the questions here is how you define young, but regardless of the age, I think different patients may be in a very different place emotionally as welltrying to deal with the diagnosis. So youre absolutely right. You have to play this by situation and cant front-load the patients with data only.
You have to do this by feeling, and thats what makes our profession so interesting and filled with humility at every step. Dr Rudolph, I think you made good comments about engaging the transplant physician closest to you, whoever you send a person [to], who makes that determination many times.
Someone who is like this 51 year old, would you think of them as a young patient? How do you define a young patient with multiple myeloma, and what would be your criteria to send someone for a transplant discussion at a transplant center?
MORAVINENI: This patient has at least a standard-risk disease, definitely not a high-risk disease51 years old with no critical organ dysfunction. Most likely the patient would be motivated. Then the response to initial treatment, I also expect to be north of 90%. So I feel...all the criteria are here for this patient to get longer benefits after the initial induction therapy. I would lead the discussion as steps: what risk and stage, what are our treatment options, and which is best to go with, quadruplet or triplet. Talk to the transplant physician, and [find out whether the] patient agrees; most people would, as theres long-term benefit.
USMANI: I would add that at the age of 51, you could also anticipate this patient to be working full-time as well and trying to get back being productive again for as long as they can. So I think to your point, the level of motivation would probably be much higher.
XIA: With the bone marrow transplant, theres no overall survival [OS] benefit, only progression-free survival [PFS] benefit. With so many new medications coming up, even though the person is young, do you think we should send everybody with good performance status?
USMANI: Every preclinical trial that weve doneIve been hearing this line in so many presentations since I was a trainee. Now that we have novel agents in multiple myeloma, is there still a role for stem cell transplantation? Ive been hearing that for over 2 decades, but each clinical trial weve done demonstrates PFS benefit in favor of stem cell transplant and using high-dose melphalan. During this period, we continue to have an improvement in OS.
When we look at the 6-, 7-, or 8-year OS, it wont be any different for a disease that has a median of 10 or 12 years of survival now because we keep on moving that needle with addition of treatments on the back end. Whats important to appreciate, however, is not every patient with multiple myeloma will benefit from every drug we have. We lose about 25% to 30% of the patients with each relapse, so theres an attrition rate. The assumption that you can save up your good drugs for latermany of our patients will never get that good drug. So the approach now is to pick the best options to give the best PFS for your patient at that particular moment in time.
With that in mind, for someone whos 51 years old who probably wants to go back to his bank job and be as active and productive as he can for 5 or 6 years and not come back for a relapse treatment in 2 or 3 years, I would think about a stem cell transplant for them in that setting. But thats my view as a myeloma doctor and a transplanter. Some patients may not agree with that at all. They will say, Can we just collect stem cells and do this later? I wont argue with them; Ill just share my opinion and data with them and then let them decide.
USMANI: It looks like the overwhelming majority is voting for VRd [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone]. I would agree with that. I was [1 of the few who voted for] D-VRd [daratumumab (Darzalex), bortezomib, lenalidomide, and dexamethasone] vote because we are early adapters at my program, and since we led the GRIFFIN trial [NCT02874742], we have switched over to D-VRd for induction for most patients.
MORAVINENI: Im there with you too. [I also voted D-VRd]. Im impressed with the deep responses, and I dont feel like saving the daratumumab is the best strategy. I think the first shot is the best shot, and patients may get a great response, a deep response, to start off.
USMANI: What are the options for primary therapy? Dr Moravineni already presented the case about better deepening of response post induction with the addition of daratumumab to the frontline setting, but feel free to [speak up with your opinion].
MORAVINENI: I was very impressed with the high MRD [minimal residual disease] in standard-risk patients like this with the quadruplet [regimen].
USMANI: I think at the end of the first year, the D-VRd posttransplant arm in the GRIFFIN study had around 50% MRD negativity.1 Many people have pointed out that GRIFFIN was a randomized phase 2 study and [that] we need phase 3 data. So theres a study called PERSEUS [NCT03710603] thats fully accrued.2 Its a randomized phase 3 trial with the same design as GRIFFIN, which we are waiting on. I dont think we will get the report this year, but probably next year.
PARIKH: Have you seen any difficulty in insurance approvals for daratumumab in transplant-eligible patients?
USMANI: No, we have not because daratumumab is approved for frontline therapy with Rd [lenalidomide and dexamethasone] and with VMP [bortezomib, melphalan, and prednisone], as well as with VTd [bortezomib, thalidomide (Thalomid), dexamethasone].3 So we have not seen any issues with insurance, but the way that we are using D-VRd is only for induction. Were not doing our D-VRd post transplant consolidation or continuing daratumumab as maintenance. Were trying to get that initial benefit with the 4 cycles of induction, become a bit more consistent in the depth of response you get before stem cell transplant, and then do the same thing that we typically do for a standard-risk patient after that.
What proportion of patients with newly diagnosed myeloma are considered young, fit, and transplant eligible in your practices?
MORAVINENI: I would say about 30% to 40%, and they are in waves from year to year, but in general, at maximum, around 40%.
KATRAGADDA: In my practice, its about 40% to 50% [of patients] who are very clearly transplant eligible, but then I would refer some borderline patients who I was not sure would be eligible. Sometimes, if you have an aggressive transplanter, then they would get transplant. So it might go up to 60% depending on those borderline patients.
USMANI: The general consensus Im getting is somewhere between 35% and 45%even 50% for some of you.
What aspects of therapy are most important to you in treatment of newly diagnosed disease?
RUDOLPH: We talked about the GRIFFIN trial, and Ive been torn between doing VRd, as I always did vs adding daratumumab to it. What do you do for the future? There are other options, but daratumumab is a pretty good drug, and you want to get your maximum response, a deep response, in your first line of treatment. Id love your thoughts [about] VRd vs D-VRd. Ive started a recent new patient on D-VRd.
USMANI: We thought long and hard about this as well, and thats why we utilized daratumumab in the induction-therapy setting. With that approach, we are trying to get patients into as good a response as possible during that first year of diagnosis. Now if you look at a standard-risk patient who got D-VRd 5 years ago and is relapsing now, are they refractory to daratumumab? No, they only got it for 4 months and have 4 or more years of PFS benefit from that intervention.
Can you use that again with something else that the patients havent seen? Sure you canyou can use daratumumab with Kd [carfilzomib (Kyprolis) and dexamethasone]; you can use it with Vd [bortezomib and dexamethasone]. If they are on lenalidomide maintenance, you wont be able to use it with lenalidomide, but you would be able to use daratumumab again at that next line of treatment. Thats how were thinking about utilizing daratumumab for those standard-risk patients and deepening response during that first year of diagnosisjust the first 4 months of treatment [are] all youre exposing them to [because] youre trying to get them into a really good deep response and...to MRD negativity in that first [year] or so.
Thats our approach, and thats why I was saying were not using daratumumab post transplant for consolidation or as part of maintenance treatment in that scenario. But Im just sharing my own practice and opinion.
As we talked about those standard-of-care regimens, what do you consider standard of care for induction? The vast majority of you have already identified VRd, but do you use any of these other ones? Do you use CyBorD [cyclophosphamide, bortezomib, and dexamethasone] or KRd [carfilzomib, lenalidomide, and dexamethasone] in this setting? What are your thoughts around these other standard-of-care regimens for induction?
RUDOLPH: I have used CyBorD, particularly for a patient who has significant renal insufficiency. Its a little bit better tolerated than VRd. I have not used some of the other regimens, just pretty much those 2. Ive also used just lenalidomide and dexamethasone.
THOMAS: Ive used the CyBorD when they present with acute renal insufficiency to get the renal insufficiency corrected, and then I switch them over generally to VRd. I think youre persuading me to add daratumumab to the VRd regimen. Ive been tempted. I had one of the concerns of the other colleagues, which was getting it paid for. I was a little bit concerned about that in the standard-risk patients, and I also think I had the misperception that if you started [daratumumab] early on, you were going to keep going on with it in the maintenance phase. But thats good to know you only need 4 cycles and then get them into a deep response, transplant, and then do the lenalidomide maintenance. Then you can reuse it, it sounds like, down the road. I do have a patient whos 88 years old I just started on DRd, and so far, theyve done very well.
XIA: If this patient presented with severe renal insufficiencyhis kidney function is very bad, he needs dialysis, and I dont think his kidney function would go back to normal or back to lowin this situation, what kind of regimen are you going to put in induction? This is for both transplant-eligible and -ineligible patients. Do you use CyBorD? Or can you use some other thing that is effective?
USMANI: In that situation, if they have standard-risk disease and theyre tolerating CyBorD fine, this is where you fine-tune things for patients. I would keep them on CyBorD in that scenario. If they have high-risk features, I would switch them over to the lower dose of lenalidomide. Lenalidomide is not contraindicated for renal, CKD [chronic kidney disease], or even patients with hemodialysis. You just have to dose it in a different way. You can reduce the dosing as well as the schedule of lenalidomide for those patients. For high-risk patients, thats the switch that I would make. The subcutaneous formulation of daratumumab would be a reasonable addition to get a good depth of response. Daratumumab plus CyBorD is now approved for systemic amyloid light-chain amyloidosis as well, so its an FDA-approved regimen. You can use it to deepen the response for those patients utilizing that indication. We have not had any issues adding daratumumab to CyBorD for our patients either. There are phase 2 data now with an amyloidosis phase 3 trial; you can justify to the insurance companies using it if they raise a concern.
MORAVINENI: How do you typically dose the lenalidomide in the patients with moderate to severe CKD?
USMANI: You would typically go down to 5 mg to start off with. You wont start with 25 mg. I would typically start with 5 mg every other day; I would go even a bit more conservative than whats on the package insert and then change it over to the 5 mg every day, the way that the package insert says. But start off with [dosing every other day].
MORAVINENI: That also aligns with their dialysis. I believe that way youre alternating them in the nondialysis days.
References:
1. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. doi:10.1182/blood.2020005288
2. Sonneveld P, Broijl A, Gay F, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS). J Clin Oncol. 2019;37(suppl 15):TPS8055. doi:10.1200/JCO.2019.37.15_suppl.TPS8055
3. NCCN. Clinical Practice Guidelines in Oncology. Multiple myeloma, version 2.2022. Accessed October 24, 2021. https://bit.ly/3F1nI79
Read the original here:
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
- Sight Care Reviews - Overpriced or Worth the Hype? SightCare Pills ... - Journal of the San Juan Islands - November 9th, 2023
- 6 Amazing Health Benefits Of Giloy (Tinospora cordifolia) - WION - November 9th, 2023
Recent Comments